BNT162b2

E812198

COVID-19 vaccine Pfizer–BioNTech COVID-19 vaccine SARS-CoV-2 vaccine mRNA vaccine pharmaceutical product

BNT162b2 is an mRNA-based COVID-19 vaccine, co-developed by BioNTech and Pfizer, that became one of the first widely authorized vaccines against SARS-CoV-2.

Try in SPARQL Jump to: Surface forms Disambiguation Statements Elicitation Referenced by

All labels observed (2)

Label	Occurrences
BNT162b2 canonical	3
Pfizer–BioNTech COVID‑19 vaccine	2

How this entity was disambiguated

This entity first appeared as the object of triple T9632093 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.

NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07

Target entity: BNT162b2
Context triple: [BioNTech, developed, BNT162b2]

A. Vaxzevria COVID-19 vaccine
Vaxzevria COVID-19 vaccine is a viral vector coronavirus vaccine created to prevent COVID-19 infection and severe disease in adults.
B. Sinovac
Sinovac is a Chinese biopharmaceutical company best known globally for developing the inactivated COVID-19 vaccine CoronaVac.
C. REGN-COV2
REGN-COV2 is a monoclonal antibody cocktail designed to prevent and treat COVID-19 by targeting the SARS-CoV-2 virus.
D. Janssen COVID-19 Vaccine
The Janssen COVID-19 Vaccine is a single-dose, viral vector-based coronavirus vaccine developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, for the prevention of COVID-19.
E. Omicron
Omicron is a vowel letter of the Greek alphabet, historically representing a short "o" sound and used today in various scientific and mathematical contexts.
F. None of above. chosen
G. Unsure - the case is ambiguous/there is not enough information to decide.

NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07

Target entity: BNT162b2
Target entity description: BNT162b2 is an mRNA-based COVID-19 vaccine, co-developed by BioNTech and Pfizer, that became one of the first widely authorized vaccines against SARS-CoV-2.

A. Vaxzevria COVID-19 vaccine
Vaxzevria COVID-19 vaccine is a viral vector coronavirus vaccine created to prevent COVID-19 infection and severe disease in adults.
B. Sinovac
Sinovac is a Chinese biopharmaceutical company best known globally for developing the inactivated COVID-19 vaccine CoronaVac.
C. REGN-COV2
REGN-COV2 is a monoclonal antibody cocktail designed to prevent and treat COVID-19 by targeting the SARS-CoV-2 virus.
D. Janssen COVID-19 Vaccine
The Janssen COVID-19 Vaccine is a single-dose, viral vector-based coronavirus vaccine developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, for the prevention of COVID-19.
E. Omicron
Omicron is a vowel letter of the Greek alphabet, historically representing a short "o" sound and used today in various scientific and mathematical contexts.
F. None of above. chosen

Statements (51)

Predicate	Object
instanceOf	COVID-19 vaccine ⓘ Pfizer–BioNTech COVID-19 vaccine ⓘ SARS-CoV-2 vaccine ⓘ mRNA vaccine ⓘ pharmaceutical product ⓘ
contains	nucleoside-modified mRNA ⓘ
deliverySystem	lipid nanoparticle ⓘ
encodesProtein	SARS-CoV-2 S protein NERFINISHED ⓘ SARS-CoV-2 spike glycoprotein NERFINISHED ⓘ
encodesRegion	full-length prefusion stabilized spike protein ⓘ
hasAgeIndication	adolescents ⓘ adults ⓘ children ⓘ
hasAlternativeName	Comirnaty NERFINISHED ⓘ Pfizer–BioNTech COVID-19 vaccine NERFINISHED ⓘ
hasATCCode	J07BX03 ⓘ
hasCommonAdverseEffects	fatigue GENERATED ⓘ headache GENERATED ⓘ injection site pain GENERATED ⓘ myalgia GENERATED ⓘ
hasDeveloper	BioNTech NERFINISHED ⓘ Pfizer NERFINISHED ⓘ
hasDoseInterval	21 days between first and second dose ⓘ
hasDosingSchedule	two-dose primary series ⓘ
hasFirstAuthorizationDate	2020-12-02 ⓘ
hasIndication	prevention of COVID-19 in humans ⓘ
hasInitialAdultDose	30 micrograms mRNA ⓘ
hasInitialAdultDoseVolume	0.3 mL ⓘ
hasMechanismOfAction	elicits cellular immune response to SARS-CoV-2 spike protein ⓘ induces neutralizing antibodies against SARS-CoV-2 spike protein ⓘ
hasPrimaryInjectionSite	deltoid muscle ⓘ
hasRareAdverseEffects	myocarditis ⓘ pericarditis ⓘ
hasRegulatoryApproval	Conditional Marketing Authorization by European Medicines Agency ⓘ Emergency Use Authorization by U.S. FDA NERFINISHED ⓘ WHO Emergency Use Listing NERFINISHED ⓘ
hasReportedEfficacy	approximately 95% efficacy against symptomatic COVID-19 in initial Phase 3 trial GENERATED ⓘ
hasRouteOfAdministration	intramuscular injection ⓘ
hasStabilityAfterThawing	limited stability at refrigerator temperatures ⓘ
hasStorageRequirement	ultra-low temperature freezing ⓘ
hasStorageTemperature	approximately −70 °C ⓘ
hasUSBrandName	Comirnaty NERFINISHED ⓘ
hasUSFDAEUAdate	2020-12-11 ⓘ
hasUSFDALicensureDate	2021-08-23 ⓘ
isCoDevelopedBy	BioNTech SE NERFINISHED ⓘ Pfizer Inc. NERFINISHED ⓘ
targetsDisease	COVID-19 NERFINISHED ⓘ
targetsVirus	SARS-CoV-2 NERFINISHED ⓘ
vaccinePlatform	mRNA ⓘ
wasFirstAuthorizedIn	United Kingdom NERFINISHED ⓘ
wasKeyTrial	Phase 3 trial NCT04368728 ⓘ

How these facts were elicited

Referenced by (5)

Full triples — surface form annotated when it differs from this entity's canonical label.

BioNTech → developed → BNT162b2 ⓘ

Pfizer–BioNTech → notableWork → BNT162b2 ⓘ

Pfizer–BioNTech → developed → BNT162b2 ⓘ

this entity surface form: Pfizer–BioNTech COVID‑19 vaccine

Pfizer–BioNTech → hasRegulatoryApprovalFor → BNT162b2 ⓘ